S'abonner

Targeted deep sequencing identifies rare loss-of-function variants in IFNGR1 for risk of atopic dermatitis complicated by eczema herpeticum - 04/12/15

Doi : 10.1016/j.jaci.2015.06.047 
Li Gao, MD, PhD a, Lianghua Bin, PhD j, , Nicholas M. Rafaels, MS a, Lili Huang, MS a, Joseph Potee, MS a, Ingo Ruczinski, PhD b, Terri H. Beaty, PhD c, Amy S. Paller, MD d, Lynda C. Schneider, MD e, Rich Gallo, MD, PhD f, Jon M. Hanifin, MD g, Lisa A. Beck, MD h, Raif S. Geha, MD i, Rasika A. Mathias, ScD a, Kathleen C. Barnes, PhD a, , , Donald Y.M. Leung, MD, PhD j
a Johns Hopkins Asthma & Allergy Center, Johns Hopkins University School of Medicine, Baltimore, Md 
b Department of Biostatistics, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Md 
c Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Md 
d Departments of Dermatology and Pediatrics, Northwestern University Feinberg School of Medicine and Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Ill 
e Division of Allergy and Immunology, Boston Children's Hospital, Boston, Mass 
f Division of Dermatology, University of California San Diego, San Diego, Calif 
g Department of Dermatology, Oregon Health & Science University, Portland, Ore 
h Department of Dermatology, University of Rochester Medical Center, Rochester, NY 
i Department of Pediatrics, Harvard Medical School, Boston, Mass 
j Department of Pediatrics, National Jewish Health, Denver, Colo 

Corresponding author: Kathleen C. Barnes, PhD, Johns Hopkins Asthma & Allergy Center, 5501 Hopkins Bayview Circle, Rm 3A.62, Baltimore, MD 21224.

Abstract

Background

A subset of atopic dermatitis is associated with increased susceptibility to eczema herpeticum (ADEH+). We previously reported that common single nucleotide polymorphisms (SNPs) in the IFN-γ (IFNG) and IFN-γ receptor 1 (IFNGR1) genes were associated with the ADEH+ phenotype.

Objective

We sought to interrogate the role of rare variants in interferon pathway genes for the risk of ADEH+.

Methods

We performed targeted sequencing of interferon pathway genes (IFNG, IFNGR1, IFNAR1, and IL12RB1) in 228 European American patients with AD selected according to their eczema herpeticum status, and severity was measured by using the Eczema Area and Severity Index. Replication genotyping was performed in independent samples of 219 European American and 333 African American subjects. Functional investigation of loss-of-function variants was conducted by using site-directed mutagenesis.

Results

We identified 494 single nucleotide variants encompassing 105 kb of sequence, including 145 common, 349 (70.6%) rare (minor allele frequency <5%), and 86 (17.4%) novel variants, of which 2.8% were coding synonymous, 93.3% were noncoding (64.6% intronic), and 3.8% were missense. We identified 6 rare IFNGR1 missense variants, including 3 damaging variants (Val14Met [V14M], Val61Ile, and Tyr397Cys [Y397C]) conferring a higher risk for ADEH+ (P = .031). Variants V14M and Y397C were confirmed to be deleterious, leading to partial IFNGR1 deficiency. Seven common IFNGR1 SNPs, along with common protective haplotypes (2-7 SNPs), conferred a reduced risk of ADEH+ (P = .015-.002 and P = .0015-.0004, respectively), and both SNP and haplotype associations were replicated in an independent African American sample (P = .004-.0001 and P = .001-.0001, respectively).

Conclusion

Our results provide evidence that both genetic variants in the gene encoding IFNGR1 are implicated in susceptibility to the ADEH+ phenotype.

Le texte complet de cet article est disponible en PDF.

Key words : IFNGR1, genetic variants, atopic dermatitis, eczema herpeticum

Abbreviations used : AD, ADEH+, ADEH−, ADRN, EASI, EH, GAS, HSV, IFNGR1, LD, MAF, NIH, pSTAT1, QC, SNP, STAT1, UTR, WT


Plan


 Supported by the Atopic Dermatitis Research Network National Institutes of Health/National Institute of Allergy and Infectious Diseases contracts HHSN272201000020C and HHSN272201000017C. K.C.B. was supported in part by the Mary Beryl Patch Turnbull Scholar Program. D.Y.M.L. was supported in part by the Edelstein Family Chair in Pediatric Allergy-Immunology. The CTRC is supported in part by NIH/NCATS Colorado CTSI grant no. UL1 TR000154.
 Disclosure of potential conflict of interest: L. Gao, N. M. Rafaels, and L. Huang have received grants from the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID). J. Potee, R. A. Mathias, and D. Y. M. Leung have received grants from the NIH. T. H. Beaty has received grants from the National Heart, Lung, and Blood Institute (NHLBI). A. S. Paller has received grants and travel support from the Atopic Dermatitis Research Network; has consultant arrangements with Anacor, Chugai-Pharma, Galderma, GlaxoSmithKline-Stiefel, Novartis, Promius Pharma, and Regeneron; and is an investigator for Abbvie, Anacor, and Astellas. L. D. Schneider has received grants from the Atopic Dermatitis Research Network, the NIH, and the NIAID. L. A. Beck has received grants from the NIAID–Atopic Dermatitis Research Network; has consultant arrangements with Regeneron, Celgene, Novartis, MedImmune, AbbVie, Unilever, Genentech, and Array Biopharma; and has stock/stock options in Wyeth. K. C. Barnes has received grants from the NIH, is employed by Johns Hopkins University, and has received royalties from UpToDate. The rest of the authors declare that they have no relevant conflicts of interest.


© 2015  American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 136 - N° 6

P. 1591-1600 - décembre 2015 Retour au numéro
Article précédent Article précédent
  • Large maculopapular cutaneous lesions are associated with favorable outcome in childhood-onset mastocytosis
  • Tim Wiechers, Anja Rabenhorst, Tina Schick, Liane M. Preussner, Anja Förster, Peter Valent, Hans-Peter Horny, Karl Sotlar, Karin Hartmann
| Article suivant Article suivant
  • Efficacy of baked milk oral immunotherapy in baked milk–reactive allergic patients
  • Michael R. Goldberg, Liat Nachshon, Michael Y. Appel, Arnon Elizur, Michael B. Levy, Eli Eisenberg, Hugh A. Sampson, Yitzhak Katz

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.